Definitive Contract 75N93026C00012
Award Date 8/3/26
Potential Completion Date 6/30/27
Potential Value $24M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Carlsbad, CA 92008, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
20
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded a $14,195,727 definitive contract to Microbiotix, Inc. on November 1, 2022, to develop the PPZ series of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies. The contract carries cost-plus-fixed-fee pricing with an ultimate completion date of March 1, 2027. Place of performance is Worcester, MA. The originating broad agency...
- The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Integral Molecular Inc. for discovery and characterization of B cell epitopes against the viral pathogens RVFV, CCHFV, and EV-D68, with a ceiling value of $8.077 million and an award date of September 16, 2024. The contract carries cost-plus-fixed-fee pricing and runs through September 15, 2029. Place of performance is Philadelphia, PA. The originating solicitation was posted May 5, 2023, with a proposal...
- The National Institute of Allergy and Infectious Diseases awarded a $38.21 million definitive contract to The Leland Stanford Junior University for development of small synthetic chemical molecules as broadly active antivirals for treatment of viral infections on September 1, 2020. The contract carries cost-plus-no-fee pricing and runs through May 31, 2030. Work is performed in Palo Alto, California. The originating solicitation, posted as a pre-solicitation notice in December 2019, sought...
- <p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $28.2 million definitive contract to Venatorx Pharmaceuticals Inc. for development of therapeutic medical countermeasures for biodefense and emerging infectious diseases on September 16, 2013, under cost-plus-fixed-fee pricing with no set-aside.</p> <p>Place of performance is Malvern, Pennsylvania. The contract ceiling is $28,199,895.53 with an ultimate completion date of September 30, 2019.</p>
- <p>The National Institute of Allergy and Infectious Diseases issued a delivery order to Public Health England on September 20, 2013, under the NIAID Animal Models of Infectious Diseases 2010-2017 IDIQ for the development of virus banks, reagents, and assays for filoviruses.</p> <p>The order carries a ceiling value of $2,214,174.58 and is priced on a cost-plus-fixed-fee basis. Place of performance is Great Britain, United Kingdom. The ultimate completion date is August 31, 2018.</p>
- The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a definitive cost-plus-fixed-fee contract to 4J Therapeutics Inc. for development of an antiviral medical countermeasure on September 30, 2024, with a ceiling value of $330.1 million and ultimate completion date of March 31, 2032. The contract funds assembly of the preclinical package for LNA14, performance of a Phase 1A study in healthy adult human subjects, and demonstration of the awardee's programmable...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on August 25, 2015, exercising Option 4 Year 5 (Period 9/1/2019–8/31/2020) for $1,999,679 in administrative and technical support for radiation/nuclear medical countermeasure product development activities under a cost-plus-fixed-fee structure. The order supports all other task orders under the base contract through administrative and technical activities. Place of performance is Menlo Park,...
- This is a $16,927,478.76 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Abvacc, Inc., a for-profit biotechnology company. The contract is to develop a potent therapeutic monoclonal antibody targeting the Marburg virus, a highly pathogenic filovirus. This award aligns with NIAID's efforts to advance medical countermeasures against biodefense and emerging infectious...
- <p>The National Institute of Allergy and Infectious Diseases awarded a $4,916,990 definitive contract to Peraton Inc. for the Viral Bioinformatics Resource Center on September 15, 2014, with no set-aside applied.</p> <p>The contract was structured as cost-plus-no-fee, with a ceiling value of $23,385,247.30 and an ultimate completion date of November 14, 2019. Place of performance is West McLean, VA.</p>
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Phase II contract to Nowdiagnostics, Inc., a small disadvantaged business, for a multiplexed remote system for filovirus disease surveillance. The firm-fixed-price contract, with a potential value of $2,431,860.00, was awarded on September 20, 2018 and has a completion date of September 30, 2022....